CN Patent

CN113286885A — 用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法

Assigned to Novartis AG · Expires 2021-08-20 · 5y expired

What this patent protects

本披露涉及用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法。具体地，涉及在患有确诊的心血管疾病的患者中，用经缀合的反义化合物ISIS 681257或其盐降低心血管事件的风险的方法。

USPTO Abstract

本披露涉及用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法。具体地，涉及在患有确诊的心血管疾病的患者中，用经缀合的反义化合物ISIS 681257或其盐降低心血管事件的风险的方法。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN113286885A
Jurisdiction: CN
Classification: —
Expires: 2021-08-20
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.